Literature DB >> 14512174

Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.

Enrico Fainardi1, Roberta Rizzo, Loredana Melchiorri, Luca Vaghi, Massimiliano Castellazzi, Andrea Marzola, Vittorio Govoni, Ezio Paolino, Maria Rosaria Tola, Enrico Granieri, Olavio Roberto Baricordi.   

Abstract

We have investigated the presence of non-classical soluble HLA-G molecules (sHLA-G) in cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients and the possible relationships between CSF levels of sHLA-G, classical soluble HLA-I (sHLA-I) molecules, IL-10 amounts and Magnetic Resonance Imaging (MRI) findings were evaluated. We studied by ELISA technique the sHLA-I, sHLA-G and IL-10 levels in CSF of 50 relapsing-remitting (RR) MS patients stratified according to clinical and MRI evidence of disease activity. Thirty-six patients with other inflammatory neurological disorders (OIND) and 41 with non-inflammatory neurological disorders (NIND) were used as controls. CSF mean levels were significantly higher in MS and OIND than in NIND for sHLA-I (p<0.001) and in MS than in controls for sHLA-G (p<0.001), with no differences among the various groups for IL-10 mean concentrations. An increase in CSF sHLA-I was found in MS patients with Gd-enhancing lesions (p<0.01), while sHLA-G and IL-10 were more represented in MS patients without lesional activity on MRI scans (p<0.02). In MRI-inactive MS, CSF IL-10 mean concentrations were significantly greater in patients with CSF-detectable levels of sHLA-G than in those without any evidence of CSF sHLA-G expression (p<0.05). Our findings suggest that CSF classical sHLA-I and non-classical sHLA-G levels may modulate MS activity as assessed by MRI acting in opposite directions. The association observed between sHLA-G and IL-10 when Gd-enhancing lesion resolved indicates a potential immunoregulatory role for IL-10 in the control of MS disease activity by shifting the sHLA-I/sHLA-G balance towards sHLA-G response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512174     DOI: 10.1016/s0165-5728(03)00266-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

Review 1.  HLA-G: a look back, a look forward.

Authors:  Edgardo D Carosella; Joel LeMaoult
Journal:  Cell Mol Life Sci       Date:  2010-11-19       Impact factor: 9.261

Review 2.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

Review 3.  Emerging topics and new perspectives on HLA-G.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Marina Stignani; Fabio Morandi; Gwenaëlle Sana; Rafael Gonzalez; Vito Pistoia; Olavio Roberto Baricordi; Etienne Sokal; Josè Peña
Journal:  Cell Mol Life Sci       Date:  2010-11-16       Impact factor: 9.261

Review 4.  New aspects in celiac disease.

Authors:  M I Torres; M A López Casado; A Ríos
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

Review 5.  Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions.

Authors:  Daria Bortolotti; Valentina Gentili; Antonella Rotola; Enzo Cassai; Roberta Rizzo; Dario Di Luca
Journal:  World J Methodol       Date:  2014-03-26

6.  Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.

Authors:  Fabio Morandi; Consuelo Venturi; Roberta Rizzo; Massimiliano Castellazzi; Eleonora Baldi; Maria Luisa Caniatti; Maria Rosaria Tola; Enrico Granieri; Enrico Fainardi; Antonio Uccelli; Vito Pistoia
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-28       Impact factor: 4.147

7.  Maternal asthma and microRNA regulation of soluble HLA-G in the airway.

Authors:  Jessie Nicodemus-Johnson; Bharathi Laxman; Randi K Stern; Jyotsna Sudi; Courtney N Tierney; Lourdes Norwick; Douglas K Hogarth; John F McConville; Edward T Naureckas; Anne I Sperling; Julian Solway; Jerry A Krishnan; Dan L Nicolae; Steven R White; Carole Ober
Journal:  J Allergy Clin Immunol       Date:  2013-03-25       Impact factor: 10.793

Review 8.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

9.  A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.

Authors:  Bruce A C Cree; John D Rioux; Jacob L McCauley; Pierre-Antoine F D Gourraud; Philippe Goyette; Joseph McElroy; Philip De Jager; Adam Santaniello; Timothy J Vyse; Peter K Gregersen; Daniel Mirel; David A Hafler; Jonathan L Haines; Margaret A Pericak-Vance; Alastair Compston; Stephen J Sawcer; Jorge R Oksenberg; Stephen L Hauser
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

10.  HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms.

Authors:  Thomas Vauvert F Hviid; Roberta Rizzo; Ole B Christiansen; Loredana Melchiorri; Anette Lindhard; Olavio R Baricordi
Journal:  Immunogenetics       Date:  2004-05-07       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.